Axsome has received FDA approval for in-house developed Auvelity (depression) and Symbravo (migraine). The company also has a pipeline of drugs in various stages with the notable exception of AXS-05 which has pending approval, for Alzheimer's Disease Agitation. That pending approval has a decision date of April 30th. If FDA approved, could push the market capitalization to an all-time high, exceeding the prior market capitalization of $9.5 billion. A stocks market cap is simply the stock price multiplied by the current number of shares outstanding. Below is a chart of Axsome Therapeutics. Thank you for reading.
No comments:
Post a Comment